New combo therapy targets Hard-to-Treat myeloma
NCT ID NCT07217184
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This study tests a combination of two drugs, belantamab mafodotin and isatuximab, in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to find the safest and most effective dose and see how well the combination controls the cancer. About 30 adults aged 18 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Atlanta, Georgia, 30322, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Grand Rapids, Michigan, 49546, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Fitzroy, Victoria, 3065, Australia
-
GSK Investigational Site
Salvador, Estado de Bahia, 41253-190, Brazil
-
GSK Investigational Site
São Paulo, 04537-080, Brazil
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Mexico City, 01330, Mexico
-
GSK Investigational Site
Oslo, 0450, Norway
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Pozuelo de AlarcOn Madr, 28223, Spain
-
GSK Investigational Site
Falun, SE-791 82, Sweden
Conditions
Explore the condition pages connected to this study.